Abstract: Objective To assess the clinical efficacy and safety of QZSWF in the treatment of non-alcoholic steatohepatitis (NASH).Methods A total of 138 NASH patients were randomly divided into observation group (94 patients) and control group (44 patients). Besides lifestyle interventions, patients were treated with QZSWF granule (polygonum cuspidatum, hawthorn , cassia seed) and placebo (10% QZSWF + 90% dextrin component), respectively. Clinical indicators of patients before and after treatment were observed. Adverse reactions in both groups were recorded. Results After 6 months of treatment, the liver function and hepatic steatosis of observation group significantly improved than those of control group (P<0.05). Furthermore, no severe adverse events were observed.Conclusion QZSWF has short-term benefits in improving hepatic steatosis and liver function showing high safety with little adverse reactions. It is worthy of clinical application.

Key words: Nonalcoholic steatohepatitis, QZSWF, Hepatic steatosis